Janet Woodcock

1948 -

crédits photo : Wikimedia Commons

pays de nationalité: États-Unis

langues parlées, écrites ou signées: anglais

scolarité: université Bucknell, Feinberg School of Medicine

occupation: pharmacologue, chercheur ou chercheuse, participant ou participante à un forum international

distinction reçue: Dr. Nathan Davis Award for Members of the Executive Branch in Career Public Service

Janet Woodcock est une médecin américaine. Depuis 2021, elle est commissaire de la Food and Drug Administration. En 2021, elle fait partie de la liste Les dix scientifiques de l'année de la revue Nature. Source : Wikipedia (fr)

Séries

Il n'y a rien à voir ici

Créer une nouvelle série

Œuvres

Il n'y a rien à voir ici

Créer une nouvelle œuvre

Articles 111

Date

Titre

Auteur·ices

2020-05-01

FDA Initiative for Drug Facts Label for Over-the-Counter Naloxone

Janet Woodcock
2020-07-27

Integrated Drug Reviews at the US Food and Drug Administration

Janet Woodcock
2020-08-03

Quality Testing of Difficult-to-Make Prescription Pharmaceutical Products Marketed in the US

Janet Woodcock
2020-08-01

Patient-Centered Approach to Benefit-Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non-Small-Cell Lung Cancer

Janet Woodcock
2020-09-15

Bridging the Gap at Warp Speed - Delivering Options for Preventing and Treating Covid-19

Moncef Slaoui, Janet Woodcock
2020-10-26

New Drugs Regulatory Program Modernization: Vision, Strategic Objectives, and Impact

Janet Woodcock
2020-11-01

Audio Interview: An Update from Operation Warp Speed

Eric Rubin, Lindsey R Baden, Janet Woodcock, Stephen Morrissey
2019-05-21

Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Melanoma

Janet Woodcock
2019-09-09

Improving Adverse Event Reporting for Compounded Drugs

Janet Woodcock
2019-01-01

Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease

Andrea Vergallo, Steven J Kiddle, Janet Woodcock
2019-10-09

Drug Regulation in the Era of Individualized Therapies

Peter Marks, Janet Woodcock
2019-09-27

Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma

Janet Woodcock
2018-03-23

The FDA's Approach to the Prescription Opioid Problem

Janet Woodcock
2018-05-01

Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs

Janet Woodcock, Robert J. Temple
2018-05-30

The FDA and the Next Wave of Drug Abuse - Proactive Pharmacovigilance

Janet Woodcock
2018-06-01

Expediting drug development for serious illness: Trade-offs between patient access and certainty

Janet Woodcock
2018-09-01

Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness

Janet Woodcock
2018-08-21

Combined Gabapentinoid and Opioid Use: The Consequences of Shifting Prescribing Trends

Janet Woodcock
2018-02-16

Precision pharmacology for Alzheimer's disease.

Andrea Vergallo, A Claudio Cuello, George Perry, Filippo Baldacci, Janet Woodcock, Alzheimer Precision Medicine Initiative (APMI)
2018-03-01

Medication development in opioid addiction: Meaningful clinical end points.

Nora Volkow, Janet Woodcock, Sharon Hertz
2018-02-23

Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease

Janet Woodcock, Robert J. Temple
2017-07-01

Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both

Janet Woodcock
2017-12-22

Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease

Janet Woodcock
2017-04-16

Center for Drug Evaluation and Research Perspective on Quality in Clinical Trials

Janet Woodcock
2017-07-13

Multidimensional Evidence Generation and FDA Regulatory Decision Making: Defining and Using "Real-World" Data

Janet Woodcock
2017-05-01

Review of the Drug Trials Snapshots Program of the US Food and Drug Administration: Women in Cardiovascular Drug Trials

Janet Woodcock
2017-07-06

Marshaling FDA Benefit-Risk Expertise to Address the Current Opioid Abuse Epidemic

Janet Woodcock
2017-12-01

Toward Better-Quality Compounded Drugs - An Update from the FDA.

Janet Woodcock
2017-12-01

Drug Trials Snapshots and Sexless Drug Labels-Reply.

Janet Woodcock
2017-10-27

Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.

Donna A Volpe, Janet Woodcock
2017-09-13

A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma.

Ola Landgren, Janet Woodcock
2017-02-01

Value Assessment in the Regulatory Context.

Janet Woodcock

Humain - wd:Q28822986

Bienvenue sur Inventaire

la bibliothèque de vos ami⋅e⋅s et communautés